Vascazen is a medical food to meet the dietary Omega-3 deficient needs of patients with cardiovascular disease through elevating EPA and DHA Omega-3 Fatty acids.
Pivotal Therapeutics will be launching the product at both the Canadian Cardiovascular Congress (CCC) Vancouver 2011 Conference and the American Heart Association’s (AHA) Scientific Sessions 2011, In October and November 2011, respectively.
Pivotal Therapeutics president Rachelle Mac Sweeney said the company will accept orders for Vascazen at the conferences.Sweeney said.